On December 3, Wang Jian'an, an academician of the Chinese Academy of Sciences and the director of the National Key Laboratory of Cardiovascular Implantable Devices, was honored to demonstrate two successful cases of transcatheter mitral valve edge-to-edge repair at the Humanitas University Research Hospital in Italy. This esteemed hospital is also the workplace of world-renowned interventional cardiologist Antonio Colombo, who has maintained close ties with China through numerous visits and collaborated with Wang Jian'an during the procedure.

The technologies and products developed by Academician Wang Jian'an and his team have reached ten major centers in seven European and American countries and over 200 medical centers across China. Wang Jian'an, who also serves as the Chairman of the Second Affiliated Hospital of Zhejiang University School of Medicine (hereinafter referred to as "SAHZU"), has led the 155-year-old institution into a new era of growth and development.

Under Wang Jian'an's visionary leadership, SAHZU has embraced the trends of the times and firmly advanced on the path of high-quality development. The hospital aims to voice the Chinese perspective and share Chinese stories with the global medical community. To achieve this, SAHZU has taken the first step in benchmarking against the world's best by engaging in exchanges and cooperation with top-tier international medical institutions such as UCLA Health, Johns Hopkins Hospital, Massachusetts General Hospital, and Mayo Clinic.

Through these collaborations, SAHZU has rapidly addressed areas of weakness and shortened the gap between itself and world-class institutions. From remote joint diagnosis and international joint physician training to workshops in management, telemedicine, and discipline construction, SAHZU has continuously sought to improve and innovate.

In recent years, SAHZU has placed a strong emphasis on original innovation and initiated a series of high-level clinical research projects. By establishing a complete scientific research chain and innovation translation platform, conducting clinical research training, and promoting a research paradigm shift with the "Innovation Center" as the carrier, SAHZU has effectively advanced the implementation of high-level industry-academia-research collaborative research on major diseases.

SAHZU has also leveraged the National Natural Science Foundation of China to build a systematic fund management organization system. With the mobilization and participation of the entire hospital, SAHZU has comprehensively elevated its innovation capacity and formed a unique fund culture oriented towards significant clinical research results. With "innovation" at its core and "constant pursuit of excellence and never giving up" as its wings, SAHZU has led the nation for 14 consecutive years in the total number of approved projects funded by the National Natural Science Foundation of China.

As a leader in the medical field, SAHZU boasts numerous achievements, including more than ten national platforms such as the first National Key Laboratory for Cardiovascular Implantable Devices and the first National Industry-Education Integration Innovation Platform for Cardiovascular and Cerebrovascular Implantable Devices. The hospital has ranked among the top ten in the performance evaluation of tertiary public hospitals nationwide for five consecutive years and holds the highest level, A++++, in the China Hospital Rankings released by Fudan.

In 2024, the DragonFlyTM transcatheter mitral valve closure system, independently developed by Wang Jian'an's team, completed multiple confirmatory clinical trials in Europe. This marked a significant milestone in the international influence of domestic devices and paved the way for domestic transcatheter mitral valve regurgitation products to enter the European market.

SAHZU's achievements extend beyond its walls, with its liver transplant team led by Professor Wang Weilin invited to Indonesia and Uzbekistan for multiple cases of living donor liver transplantation and complex liver and gallbladder surgery procedures. The colorectal surgery team, which developed the standard diagnosis and treatment guidelines for colorectal tumors in China, was also invited to Ulaanbaatar, Mongolia, to demonstrate difficult surgeries and received high praise from local doctors.

With eight key technologies influencing the world, including heart valve interventional procedures, pediatric liver transplantation, lung transplantation, rare disease diagnosis and treatment, malignant tumor "Hifu knife" treatment, liver cancer intervention therapy, bone tumor treatment, and cataract surgery, SAHZU has served 110 countries and regions.

In its journey towards becoming a world-class hospital, the Second Affiliated Hospital of Zhejiang University School of Medicine continues to contribute its wisdom and expertise to the global medical community.